Not many know or even heard of Mikhail Blagosklonny. He was believed in gaining all the knowledge he could in his field of expertise. You could say he practice and dedicated his life to science earning his M.D. in internal medicine and PhD in experimental medicine and cardiology. He gives back to the science community by inspiring young minds as a professor on oncology at a cancer institution. He worked nearly all his life on how to fighter cancers and determining the origins of it.
His passion continued to grow and he was elected as editor-in-chief of the Aging and Cell Cycle and the Oncotarget, made an associate editor for Cancer Biology & Therapy, and was a member on the editorial board of Cell Death & Differentiation. He was involved with many scientific matters concerning the ever changing atoms of a cancer cell and its rather peculiar properties. Follow Mikhail on Loop.
It was Blagosklonny’s belief, that the role TOR signaling in aging corresponded to cancer could be dismissed by using a fairly common cancer treatment,known as rapamycin, to aid in extending the patience lifespan. Rapamycin has also been revealed as being a lifesaver helping to decrease the risk of rejection in donated organ receivers.
As of today Mikhail Blagosklonny had managed to publish 270 papers in peer-reviewed journals with over 25,000 citations. Even though some of his journals were not accepted among some of his scientific colleagues, Mikhail Blagosklonny completed more in his career than most could only dream of completing in their lifetime. Visit ResearchGate to keep up to date with Mikhail’s latest work.